Skeletal Effects of Baricitinib vs Tocilizumab in Rheumatoid Arthritis

Nils Schulz's post hoc comparative cohort analysis compares bone mineral density changes in patients with rheumatoid arthritis treated with baricitinib or tocilizumab over 12 months. The dataset includes DXA scan results, disease activity scores, and multivariable analysis from two prospective observational cohorts. It was last updated on 2026-05-28.

Use Cases

• Compare bone density outcomes based on treatment type (baricitinib vs. tocilizumab) mentioned in the description
• Analyze the relationship between disease activity suppression and bone health based on DAS28-CRP change data
• Identify factors associated with bone mineral density change using multivariable models described in the results

Strengths

• Includes data from two prospective observational cohorts with harmonized eligibility criteria.
• Reports specific BMD change values (e.g., +8.2 mg/cm² for baricitinib spine) with 95% confidence intervals.
• License is CC-BY-4.0, allowing for open reuse and sharing.

Limitations

• Dataset is very small (17.6 KB), suggesting limited scope and sample size.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Nils Schulz via figshare

Collection Method

Post hoc comparative cohort analysis based on two prospective single-center observational studies.

Time Range

12-month observation period

Freshness

Last updated 2026-05-28 06:18:20